Harbin Jixianglong Biotech Co., Ltd. recalls

2 recalls.

• Semaglutide recall (Harbin Jixianglong Biotech Co., Ltd.)
  DrugClass IIReported March 11, 2026 · CGMP Deviations This recall has been initiated due to failing to complete process validation and bacterial endotoxin method validation before distribution
• Semaglutide recall (Harbin Jixianglong Biotech Co., Ltd.)
  DrugClass IIReported March 11, 2026 · CGMP Deviations This recall has been initiated due to failing to complete process validation and bacterial endotoxin method validation before distribution